# US 6,727,237 B2 · Inhibitors of bacterial NAD synthetase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,237 B2
- Document ID: US6727237B2
- Status: Granted
- Kind: B2
- Application number: 10/281,407
- Filed: 2002-10-25
- Published: 2004-04-01
- Granted: 2004-04-27
- Earliest claimed: 1998-01-14
- Inventors: Wayne J. Brouillette; Donald Muccio; Mark J. Jedrzejas; Christie G. Brouillette; Yancho Devedjiev; Walter Cristofoli; Lawrence J. DeLucas; Jose Gabriel Garcia; Laurent Schmitt; Sadanadan E. Velu
- Web page: https://patentgrep.com/patent/US6727237B2

## CPC

- C07D 213/80: in position 3
- A01N 43/38: condensed with carbocyclic rings
- A01N 43/40: six-membered rings
- A01N 43/42: condensed with carbocyclic rings
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 229/42: with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
- C07C 235/46: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C12Q 1/48: involving transferase
- C40B 40/00: Libraries per se, e.g. arrays, mixtures
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present invention provides methods of synthesizing and screening inhibitors of bacterial NAD synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial NAD synthetase enzyme.

## Claims

### Claim 1

A method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound.

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound microbial infection is a bacterial infection.

### Claim 3 (depends on 1)

The method of claim 1 wherein the bacterium is a gram negative or gram positive bacteria.

### Claim 4 (depends on 1)

The method of claim 1 wherein the microbial infection comprises an infection caused by an antibiotic strain of bacteria.

### Claim 5 (depends on 1)

The method of claim 1 comprising oral, rectal, intramuscularly, intravenous, intravesicular or topical administration.

### Claim 6 (depends on 1)

The method of claim 1 wherein the compound is administered in a dosage of between about 0.1 to about 15 g per day and wherein the dosage is administered from about 1 to about 4 times per day.

### Claim 7 (depends on 1)

The method of claim 1 further comprising administering a broad spectrum antibiotic.

### Claim 8

A method of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor to reduce or eliminate the production of NAD whereby the prokaryote is killed.

### Claim 9

A method of decreasing prokaryotic growth, comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased.

### Claim 10 (depends on 9)

The method of claim 9 wherein the prokaryote is a bacterium.

### Claim 11 (depends on 10)

The method of claim 10 wherein the bacterium is a gram negative or a gram positive bacteria.

### Claim 12 (depends on 9)

The method of claim 9 wherein the prokaryote is an antibiotic resistant strain of bacteria.

### Claim 13 (depends on 9)

The method of claim 9 wherein the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.

### Claim 14 (depends on 9)

The method of claim 9 wherein the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.

### Claim 15 (depends on 9)

The method of claim 9 wherein the administering step comprises oral, rectal, intramuscularly, intravenous, intravesicular or topical administration.

### Claim 16 (depends on 9)

The method of claim 9 wherein the compound is administered in a dosage of between about 0.1 to about 15 g per day and wherein the dosage is administered from about 1 to about 4 times per day.

### Claim 17 (depends on 9)

The method of claim 9, further comprising administering a broad spectrum antibiotic.
